NASDAQ : RADX

Radiopharm Theranostics Limited — Company profile

Healthcare · Biotechnology · Australia

Last price 1.1164 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.21M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avβ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.

Details

NameRadiopharm Theranostics Limited
SectorHealthcare
IndustryBiotechnology
Employees14
Founded2021
CeoRiccardo Canevari
CountryAustralia
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyAUD
IsinUS75041J1016
Cusip75041J101
Cik0001949257
Sic2834

Key executives

NameTitle
Riccardo CanevariMD, Chief Executive Officer and Director
Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder and Executive Chairman
Dr. Dimitris Voliotis M.D.Chief Medical Officer
Aaron LauritaChief Financial Officer
Hitesh GoelHead of Project Management
Nathan Jong C.A.Joint Company Secretary
Amritha SushilJoint Company Secretary

Contact

Address62 Lygon Street, Level 3, Carlton, VIC 3053, Australia
Phone61 3 9824 5254
Websitehttps://www.radiopharmtheranostics.com